Reta 30mg

Retatrutide is a next-generation investigational peptide that targets three key hormonal pathways involved in appetite, metabolism, and energy expenditure:

GLP-1, GIP, and Glucagon receptors.
This triple-agonist approach is being studied for advanced weight-management outcomes beyond current single-pathway therapies.

What It Supports

• Significant reductions in appetite and caloric intake
• Increased energy expenditure and fat oxidation
• Improved insulin sensitivity and glucose control
• Support for long-term weight-management research
• Potential improvements in cardiometabolic markers

How It Works
Retatrutide stimulates multiple metabolic receptors to amplify effects from gut-brain signaling to fat-burning pathways:

• GLP-1 → appetite reduction and slowed gastric emptying
• GIP → enhanced satiety response and metabolic flexibility
• Glucagon → increased calorie burn and fat mobilization

Together, these mechanisms create a uniquely powerful metabolic shift.

Ideal Research Applications

• Obesity and weight-management modeling
• Metabolic disease and insulin-resistance studies
• Synergistic protocols with diet and exercise variables

For Research Use Only
Not approved by the FDA for medical use. Not intended to diagnose, treat, cure, or prevent any disease. Laboratory research only.